Balance Sheet

Cash Flow Statement

Acquisitions Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Capital Expenditures Capital Expenditures Cash from Discontinued Operations Cash from Discontinued Operations Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Intangibles Change in Intangibles Change in Inventory Change in Inventory Change in Receivables Change in Receivables Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased Short-Term Debt issuances

Daily Values

Growth Metrics

Others

Accumulated Depreciation & Amortization Accumulated Depreciation & Amortization Cost of Revenue EBIAT Gross Profit Leases Long-Term Debt Issuances Long-Term Debt Repayments Machine, Furnitures, Fixtures & Other Other Gross PP&E Adjustments Other Gross PP&E Adjustments Property, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - Net Shares Issued Shares Outstanding Shares Outstanding Shares Repurchased Short-Term Debt issuances

Cumberland Pharmaceuticals (CPIX) Long-Term Debt Repayments (2017 - 2025)

Cumberland Pharmaceuticals' Long-Term Debt Repayments history spans 11 years, with the latest figure at $10.0 million for Q1 2025.

On a quarterly basis, Long-Term Debt Repayments rose 30.33% to $10.0 million in Q1 2025 year-over-year; TTM through Dec 2025 was $10.0 million, a 72.12% decrease, with the full-year FY2025 number at $10.0 million, down 72.12% from a year prior.
Long-Term Debt Repayments hit $10.0 million in Q1 2025 for Cumberland Pharmaceuticals, up from $6.3 million in the prior quarter.
Over the last five years, Long-Term Debt Repayments for CPIX hit a ceiling of $20.0 million in Q2 2022 and a floor of $6.3 million in Q4 2024.
Historically, Long-Term Debt Repayments has averaged $11.3 million across 5 years, with a median of $10.9 million in 2023.
Biggest five-year swings in Long-Term Debt Repayments: surged 76.47% in 2021 and later tumbled 45.82% in 2023.
Tracing CPIX's Long-Term Debt Repayments over 5 years: stood at $14.0 million in 2021, then crashed by 45.0% to $7.7 million in 2022, then increased by 1.8% to $7.8 million in 2023, then fell by 19.44% to $6.3 million in 2024, then skyrocketed by 58.9% to $10.0 million in 2025.
Business Quant data shows Long-Term Debt Repayments for CPIX at $10.0 million in Q1 2025, $6.3 million in Q4 2024, and $11.0 million in Q3 2024.